• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Liquidia (LQDA) Is Down 7.8% After Swing to Q2 Profit on Surging YUTREPIA Revenue - What's Changed

    Simply Wall St·08/23/2026 16:17:51
    Listen to the news
    • Liquidia Corporation recently reported past second-quarter 2026 results showing revenue of US$171.68 million versus US$8.84 million a year earlier, with net income of US$74.72 million replacing a prior net loss and basic earnings per share from continuing operations rising to US$0.84.
    • Over the first half of 2026, this shift from losses to profits and strong revenue expansion underscores how YUTREPIA’s commercialization and improved payer access are now translating more fully into the company’s reported financial performance.
    • We’ll now examine how this sharp swing to profitability and revenue growth could reshape Liquidia’s investment narrative built around YUTREPIA and L606.

    The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

    Liquidia Investment Narrative Recap

    To own Liquidia, you need to believe YUTREPIA can sustain meaningful, reimbursed use in pulmonary hypertension while L606 matures into a second pillar over time. The latest second quarter results confirm that rapid commercial ramp is already flowing through to the P&L, but they do not remove near term risks around payer terms and the company’s growing dependence on a single drug franchise.

    Among recent developments, Liquidia’s addition to the S&P 600 and S&P Composite 1500 in June 2026 looks particularly relevant. Index inclusion can broaden the shareholder base just as YUTREPIA driven revenue and earnings turn positive, potentially amplifying how any future data readouts, payer updates or IP outcomes are reflected in the share price.

    Yet beneath the strong headline revenue and profit figures, one risk investors should be aware of is how payer rebate terms and gross to net adjustments could...

    Read the full narrative on Liquidia (it's free!)

    Liquidia's narrative projects $1.4 billion revenue and $665.8 million earnings by 2029. This requires 68.6% yearly revenue growth and about a $643.5 million earnings increase from $22.3 million today.

    Uncover how Liquidia's forecasts yield a $72.38 fair value, a 5% upside to its current price.

    Exploring Other Perspectives

    LQDA 1-Year Stock Price Chart
    LQDA 1-Year Stock Price Chart

    Some of the lowest estimate analysts were already modeling about US$1.3 billion of 2029 revenue and US$586.0 million of earnings, yet they still caution that early YUTREPIA strength could be front loaded, highlighting how differently you might view today’s results and why it is worth exploring several scenarios.

    Explore 5 other fair value estimates on Liquidia - why the stock might be worth just $72.38!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Curious About Other Options?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.